RSV

BMS-433771 dihydrochloride hydrate is a selective inhibitor of respiratory syncytial virus (RSV), effectively targeting both RSV A and B strains. With an average EC50 of 20 nM, it demonstrates significant antiviral activity. This compound is valuable for research applications focused on respiratory tract diseases and the mechanisms underlying RSV infection and pathogenesis.

RSV L-protein-IN-2 is a noncompetitive inhibitor of the Respiratory Syncytial Virus (RSV) polymerase, exhibiting an IC50 value of 4.5 μM. This compound demonstrates significant antiviral activity against long strains of RSV, with an EC50 of 1.3 μM. It is applicable in research focused on developing therapeutic strategies against RSV infections and understanding viral replication mechanisms.

BTA-9881 is a potent respiratory syncytial virus (RSV) inhibitor, demonstrating EC50 values of 48 nM, 59 nM, and 160 nM against RSV A2, RSV Long, and RSV B1, respectively. Its favorable pharmacokinetic properties make it a valuable reagent for studying RSV infection and evaluating potential antiviral therapies. BTA-9881 serves as an important tool in respiratory virus research, aiding in the development of effective treatments for RSV-related diseases.

JNJ-7184 is a non-nucleoside inhibitor targeting the RSV-Large (L) polymerase. This compound exhibits potent antiviral activity, demonstrating a pEC50 of 7.86 and a pCC50 of 4.29 in HeLa cells. JNJ-7184 effectively prevents respiratory syncytial virus (RSV) replication and transcription by disrupting the initiation and early elongation stages of the viral life cycle, making it a valuable tool for research into RSV pathogenesis and potential therapeutic strategies.

AZ-27 is a selective inhibitor of respiratory syncytial virus (RSV) by targeting its polymerase activity. This compound exhibits the ability to differentially suppress various RSV polymerase functions at the promoter level, effectively inhibiting the early stages of mRNA transcription and genome replication. AZ-27 is suitable for research applications focused on understanding RSV pathogenesis and developing antiviral strategies.

AZD4316 is an inhibitor of the respiratory syncytial virus (RSV) L protein, demonstrating significant antiviral activity against RSV A subtypes, including strain A2. This compound effectively hinders viral replication during the early stages of infection, particularly at the viral entry phase. However, its efficacy diminishes when administered 12-24 hours post-infection. AZD4316 is valuable for research focused on RSV infection mechanisms and potential therapeutic strategies.

RSV-IN-13 is a selective inhibitor of respiratory syncytial virus (RSV) fusion protein, exhibiting antiviral activity. It demonstrates an EC50 of 444.2 nM against the RSV A2 strain, with a CC90 of 23.7 μM in HepG2 cells. By effectively blocking the entry of the virus into host cells, RSV-IN-13 serves as a valuable tool for research on RSV infection and pathogenesis.

A 33903 is a selective inhibitor of respiratory syncytial virus (RSV) replication. It demonstrates significant antiviral activity against RSV, making it a valuable tool for researchers studying RSV infections and related therapeutic interventions. This reagent can facilitate investigations into viral pathogenesis and the development of antiviral strategies.

4,5-O-Dicaffeoyl quinic acid methyl ester is a potent antiviral agent specifically targeting respiratory syncytial virus (RSV). It exhibits strong inhibitory activity with an IC50 value of 0.63 μg/mL, indicating effective suppression of viral replication. The compound's safety profile is substantiated by a CC50 of 118.68 μg/mL, supporting its potential use in research applications focused on RSV-related therapeutic strategies.